Nurix Therapeutics (NRIX) Equity Average (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Equity Average data on file, last reported at $509.8 million in Q1 2026.

• Equity Average for Q1 2026 came in at $509.8 million, up 1.16% year-over-year; the trailing twelve-month figure through Feb 2026 was $509.8 million (up 1.16% YoY), and the FY2025 annual result was $532.9 million, up 46.5% from the prior year.
• Equity Average grew to $509.8 million in Q1 2026 per NRIX's latest filing, from $455.5 million in the prior quarter.
• Over five years, Equity Average peaked at $509.8 million in Q1 2026 and troughed at $184.6 million in Q1 2024.
• A 5-year average of $346.0 million and a median of $323.1 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average tumbled 36.09% in 2024, then surged 172.97% in 2025.
• A 5-year view of Equity Average shows it stood at $323.1 million in 2022, then sank by 32.79% to $217.2 million in 2023, then jumped by 108.11% to $451.9 million in 2024, then grew by 0.79% to $455.5 million in 2025, then gained by 11.93% to $509.8 million in 2026.
• Business Quant data shows NRIX's Equity Average at $509.8 million in Q1 2026, $455.5 million in Q4 2025, and $409.9 million in Q3 2025.